PDF(Sci-hub)
Abstract：
We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer\'s Association guidelines for the neuropathologic assessment of Alzheimer\'s disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an \"ABC\" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.
摘要：
我们提供了一个实用指南，用于实施最近修订的美国国家衰老研究所-阿尔茨海默病协会指南，用于阿尔茨海默病（AD）的神经病理学评估。对先前共识标准的主要修订是：（1）认识到AD神经病理变化可能发生在明显没有认知障碍的情况下，（2）AD神经病理变化的“ABC”评分，包括淀粉样β沉积物的组织病理学评估（A），神经原纤维缠结分期（B），和神经炎斑块的评分（C），和（3）更详细的方法来评估常见的共病条件，如路易体病，血管性脑损伤，海马硬化,和TARDNA结合蛋白（TDP）-43免疫反应性包涵体。还建议对大脑进行最小采样，具有可接受的替代方法的首选染色方法，报告结果，和临床病理相关性。
